← Eichor
Study identifier: NCT07630974 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

Condition: Malignant Neoplasm  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 1/Phase 2
Planned participants134
Who can joinAll sexes, 1 Month to 17 Years
Healthy volunteersNo

About this study

Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids The study treatment I-DXd (also known as MK-2400 or ifinatamab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of I-DXd and if children younger than 12 years old tolerate it * How many children who receive I-DXd have the cancer get smaller or go away

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (17)

University of Iowa Hospitals ( Site 4017)Iowa City, Iowa, United StatesRecruiting
Dana Farber Cancer Center ( Site 4013)Boston, Massachusetts, United StatesRecruiting
Rutgers Cancer Institute of New Jersey ( Site 4008)New Brunswick, New Jersey, United StatesRecruiting
Memorial Sloan Kettering Cancer Center ( Site 4010)New York, New York, United StatesRecruiting
New York Medical College ( Site 4023)Valhalla, New York, United StatesRecruiting
Children's Hospital of Philadelphia (CHOP) ( Site 4021)Philadelphia, Pennsylvania, United StatesRecruiting
Intermountain - Primary Children's Hospital ( Site 4014)Salt Lake City, Utah, United StatesRecruiting
UZ Gent ( Site 4428)Ghent, Oost-Vlaanderen, BelgiumRecruiting
Rigshospitalet ( Site 4467)Copenhagen, Capital Region, DenmarkRecruiting
CENTRE LEON BERARD ( Site 4100)Lyon, Rhone, FranceRecruiting
Rambam Health Care Campus ( Site 4674)Haifa, IsraelRecruiting
Seoul National University Hospital-Pediatrics ( Site 4972)Seoul, South KoreaRecruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07630974